Restoring Low Vision: How to Strengthen Your Potentials in Low Vision and Blindness, First Edition, by Bernhard A. Sabel

.
Source: Neuro-Ophthalmology - Category: Opthalmology Authors: Source Type: research

Related Links:

Contributors : Miae Oh ; Jiah YeomSeries Type : Expression profiling by arrayOrganism : Caenorhabditis elegansLipofuscin is known as intracellular waste substance produced by damaged mitochondrial incompleted decomposition. And it is a biomarker of aging. As aging, accumulation of the lipofuscin in retinal pigment epithelium induces blindness called Age-related macular degeneration. Soraprazan is developed to reduce the lipofuscin production and cure the age-related macular degeneration. Soraprazan reducing the age biomarker lipofuscin can be suggested to have effect of longevity extension. C.elegans were treated on NGM a...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Caenorhabditis elegans Source Type: research
WEDNESDAY, Jan. 22, 2020 -- The newly approved drug teprotumumab can offer hope to adults with thyroid eye disease, a rare and potentially blinding condition. It's the first treatment specifically approved for thyroid eye disease. The drug was...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
[Vanguard] An Ophthalmologist, Dr. Adeniyi Irefin, says diabetes increases the risk of eye diseases like cataracts, glaucoma and diabetic retinopathy, which can lead to blindness if care is not taken.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
(IOS Press) Progress in research and technology is giving rise to an optimistic future for compensation and restoration of low vision, according to research in a special issue of Restorative Neurology and Neuroscience, published by IOS Press. Seven studies explore different aspects of vision loss after damage to the retina, optic nerve or brain due to diseases such as glaucoma or optic neuropathy. Remarkable progress is being made to treat conditions of partial blindness that have previously been considered irreversible.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Authors: Haritoglou C, Maier M, Neubauer AS, Augustin AJ Abstract Introduction: Diabetic macular edema (DME) is a sight threatening disease and a major cause for blindness for people in working age. The pathogenesis is multifactorial and complex. The pharmacotherapy of DME addresses both the inhibition of vascular endothelial growth factor (VEGF) by the intravitreal injection of VEGF inhibitors and inflammatory processes by the intravitreal application of steroids. Several trials have been published reporting on the efficacy and safety of these treatments.Areas covered: This review discusses original research artic...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Background/Purpose: The role of blood malondialdehyde (MDA) in age-related macular degeneration (AMD), the leading cause of new blindness in industrialized countries, is still matter of debate. We performed a systematic review and meta-analysis of the published data on the MDA levels in AMD patients. Methods: PubMed, ISI Web of Sciences, and Scopus searches were performed according to MOOSE guidelines. Case–control studies were eligible for inclusion. Participants and controls were AMD patients and subjects without AMD, respectively. The main outcome measures were wet AMD and dry AMD. MDA level was the main expo...
Source: RETINA - Category: Opthalmology Tags: Review Source Type: research
Chemical neuromodulation of the retina using native neurotransmitters to biomimetically activate target retinal neurons through chemical synapses is a promising biomimetic alternative to electrical stimulation for restoring vision in blindness caused by photoreceptor degenerative diseases. Recent research has shown that subretinal chemical stimulation could be advantageous for treating photoreceptor degenerative diseases but many of the parameters for achieving efficacious chemical neuromodulation are yet to be explored. In this paper, we investigated how the depth at which neurotransmitter is injected subretinally affects...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
The field of medical AI is buzzing. More and more companies set the purpose to disrupt healthcare with the help of artificial intelligence. Given how fast these companies come and go, it can prove to be hard to stay up-to-date with the most promising ones. Here, I collected the biggest names currently on the market ranging from start-ups to tech giants to keep an eye on in the future. To further help you keep up with what A.I. brings to medicine, The Medical Futurist team made an easy-to-digest e-book about just that. I highly encourage you to read it and would love to hear about your thoughts! Artificial Intelligence has ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence Healthcare Design AI digital health genetics Innovation Personalized medicine pharma GC1 big data drug development healthcare companies medical imaging Source Type: blogs
(Flinders University) Researchers have identified 107 genes that increase a person's risk of developing the eye disease glaucoma, and now developed a genetic test to detect those at risk of going blind from it. The research, led by QIMR Berghofer Medical Research Institute and Flinders University in Australia, has been published today in the international Nature Genetics journal.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractPurpose of ReviewCorneal diseases are a major cause of blindness worldwide, resulting from corneal scarring and neovascularization. There is an unmet need for developing effective therapies to prevent and/or treat corneal neovascularization.Recent FindingsTopical steroid medication, cautery, argon and yellow dye laser, and fine needle diathermy have all been advocated with varying degrees of success. Vascular endothelial growth factor family of proteins play a pivotal role in corneal neovascularization, and current therapies are aimed at disrupting the various steps in this pathway. Advancement in cell-based therap...
Source: Current Pathobiology Reports - Category: Laboratory Medicine Source Type: research
More News: Blindness | Brain | Neurology | Opthalmology